Accumulation of segmental alterations determines progression in neuroblastoma

Journal of Clinical Oncology

Volumn 28, Issue 19, 2010, Pages 3122-3130

  Schleiermacher, Gudrun ^a   Janoueix Lerosey, Isabelle ^a   Ribeiro, Agnès ^a   Klijanienko, Jerzy ^a   Couturier, Jérôme ^a   Pierron, Gaëlle ^a   Mosseri, Véronique ^a   Valent, Alexander ^a   Auger, Nathalie ^a   Plantaz, Dominique ^a   Rubie, Hervé ^a   Valteau Couanet, Dominique ^a   Bourdeaut, Franck ^a   Combaret, Valérie ^a   Bergeron, Christophe ^a   Michon, Jean ^a   Delattre, Olivier ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER RELAPSE; CHROMOSOME BREAKAGE; CLINICAL ASSESSMENT; COMPARATIVE GENOMIC HYBRIDIZATION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; GENETIC RISK; GENOME; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR EVOLUTION; NEUROBLASTOMA; ONSET AGE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; TRIPLOIDY; TUMOR GROWTH; CANCER STAGING; CHILD; CHROMOSOME ABERRATION; DISEASE COURSE; GENETICS; INFANT; KAPLAN MEIER METHOD; METHODOLOGY; MULTIVARIATE ANALYSIS; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; TUMOR RECURRENCE;

CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOME BREAKPOINTS; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE PROGRESSION; HUMANS; INFANT; INFANT, NEWBORN; KAPLAN-MEIERS ESTIMATE; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEUROBLASTOMA; PROGNOSIS;

EID: 77955477995     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.7955     Document Type: Article

References (44)

1. Brodeur GM: Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3:203-216, 2003
2. Maris JM, Hogarty MD, Bagatell R, et al: Neuroblastoma. Lancet 369:2106-2120, 2007 (Pubitemid 46935947)
3. Bagatell R, Rumcheva P, London WB, et al: Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol 23:8819-8827, 2005 (Pubitemid 46211528)
4. Ladenstein R, Ambros IM, Potschger U, et al: Prognostic significance of DNA di-tetraploidy in neuroblastoma. Med Pediatr Oncol 36:83-92, 2001
5. Look AT, Hayes FA, Nitschke R, et al: Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 311:231-235, 1984 (Pubitemid 14087665)
6. Schneiderman J, London WB, Brodeur GM, et al: Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: A report from the Children's Oncology Group. J Clin Oncol 26:913-918, 2008 (Pubitemid 351398084)
7. George RE, London WB, Cohn SL, et al: Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 23:6466-6473, 2005 (Pubitemid 46190237)
8. Seeger RC, Brodeur GM, Sather H, et al: Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 313:1111-1116, 1985 (Pubitemid 16216827)
9. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al: Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 27:1026-1033, 2009
10. Attiyeh EF, London WB, Mosse YP, et al: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 353:2243-2253, 2005 (Pubitemid 41697287)
11. Bown N, Cotterill S, Lastowska M, et al: Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med 340: 1954-1961, 1999
12. Caron H, van Sluis P, de Kraker J, et al: Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 334:225-230, 1996 (Pubitemid 26030673)
13. Plantaz D, Vandesompele J, Van Roy N, et al: Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification. Int J Cancer 91:680-686, 2001 (Pubitemid 32115264)
14. Rubie H, Delattre O, Hartmann O, et al: Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: Results of the French NBL 90 Study: Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP). Eur J Cancer 33:1917-1922, 1997
15. Schleiermacher G, Delattre O, Peter M, et al: Clinical relevance of loss heterozygosity of the short arm of chromosome 1 in neuroblastoma: A single-institution study. Int J Cancer 69:73-78, 1996 (Pubitemid 26164859)
16. Lastowska M, Cullinane C, Variend S, et al: Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 19:3080-3090, 2001 (Pubitemid 32565447)
17. Michels E, Vandesompele J, De Preter K, et al: Array CGH-based classification of neuroblastoma into genomic subgroups. Genes Chromosomes Cancer 46:1098-1108, 2007 (Pubitemid 47614544)
18. Mosse YP, Diskin SJ, Wasserman N, et al: Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer 46:936-949, 2007 (Pubitemid 47435023)
19. Schleiermacher G, Michon J, Huon I, et al: Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br J Cancer 97:238-246, 2007 (Pubitemid 47057465)
20. Tomioka N, Oba S, Ohira M, et al: Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 27:441-449, 2008
21. Vandesompele J, Baudis M, De Preter K, et al: Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 23:2280-2299, 2005 (Pubitemid 46218721)
22. Vandesompele J, Speleman F, Van Roy N, et al: Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: How many genetic subgroups are there? Med Pediatr Oncol 36:5-10, 2001
23. Carr J, Bown NP, Case MC, et al: High-resolution analysis of allelic imbalance in neuroblastoma cell lines by single nucleotide polymorphism arrays. Cancer Genet Cytogenet 172:127-138, 2007 (Pubitemid 46043573)
24. George RE, Attiyeh EF, Li S, et al: Genomewide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One 2:e255, 2007
25. Selzer RR, Richmond TA, Pofahl NJ, et al: Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer 44:305-319, 2005 (Pubitemid 41397100)
26. Stallings RL, Nair P, Maris JM, et al: High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma. Cancer Res 66:3673-3680, 2006
27. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993 (Pubitemid 23228250)
28. Hupe P, Stransky N, Thiery JP, et al: Analysis of array CGH data: From signal ratio to gain and loss of DNA regions. Bioinformatics 20:3413-3422, 2004 (Pubitemid 40136776)
29. La Rosa P, Viara E, Hupe P, et al: VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics 22:2066-2073, 2006 (Pubitemid 44390895)
30. Hero B, Simon T, Spitz R, et al: Localized infant neuroblastomas often show spontaneous regression: Results of the prospective trials NB95-S and NB97. J Clin Oncol 26:1504-1510, 2008
31. Hiyama E, Iehara T, Sugimoto T, et al: Effectiveness of screening for neuroblastoma at 6 months of age: A retrospective population-based cohort study. Lancet 371:1173-1180, 2008
32. Schilling FH, Spix C, Berthold F, et al: Neuroblastoma screening at one year of age. N Engl J Med 346:1047-1053, 2002
33. Woods WG, Gao RN, Shuster JJ, et al: Screening of infants and mortality due to neuroblastoma. N Engl J Med 346:1041-1046, 2002
34. Kerbl R, Urban CE, Ambros IM, et al: Neuroblastoma mass screening in late infancy: Insights into the biology of neuroblastic tumors. J Clin Oncol 21:4228-4234, 2003
35. Noutomi Y, Oga A, Uchida K, et al: Comparative genomic hybridization reveals genetic progression of oral squamous cell carcinoma from dysplasia via two different tumourigenic pathways. J Pathol 210:67-74, 2006 (Pubitemid 44288182)
36. Paulson TG, Maley CC, Li X, et al: Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res 15:3305-3314, 2009
37. Janoueix-Lerosey I, Novikov E, Monteiro M, et al: Gene expression profiling of 1p35-36 genes in neuroblastoma. Oncogene 23:5912-5922, 2004 (Pubitemid 39093535)
38. Wang Q, Diskin S, Rappaport E, et al: Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 66:6050-6062, 2006
39. Janoueix-Lerosey I, Hupe P, Maciorowski Z, et al: Preferential occurrence of chromosome breakpoints within early replicating regions in neuroblastoma. Cell Cycle 4:1842-1846, 2005
40. Schleiermacher G, Bourdeaut F, Combaret V, et al: Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain. Oncogene 24:3377-3384, 2005 (Pubitemid 40695119)
41. Schleiermacher G, Janoueix-Lerosey I, Combaret V, et al: Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genet Cytogenet 141:32-42, 2003 (Pubitemid 36165194)
42. Kim H, Chen J: New players in the BRCA1- mediated DNA damage responsive pathway. Mol Cells 25:457-461, 2008
43. Hoeijmakers JH: Genome maintenance mechanisms for preventing cancer. Nature 411:366-374, 2001
44. Mullighan CG, Phillips LA, Su X, et al: Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322:1377-1380, 2008 (Pubitemid 352775249)